Intelence
Etravirine 100.0 mg
What it does
Etravirine is an antiviral medication used to treat HIV infection.
Commonly used for: HIV infection (human immunodeficiency virus), AIDS (acquired immune deficiency syndrome)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Zambia Medicines Regulatory Authority · fetched 2026-03-12 00:06:15 · updated 2026-09-28 03:38:17
Drug Interactions
27Severe (5)
Benzodiazepines - increases exposure
Etravirine is predicted to increase the exposure to benzodiazepines (diazepam). Avoid.
Diazepam - increases exposure
Etravirine is predicted to increase the exposure to benzodiazepines (diazepam). Avoid.
Etravirine - decreases exposure
St John’s wort is predicted to decrease the exposure to etravirine. Avoid.
Mobocertinib - decreases exposure
Etravirineispredictedtodecreasetheexposureto mobocertinib.Avoid.rTheoretical
Zanubrutinib - decreases exposure
Etravirineispredictedtodecreasetheexposureto zanubrutinib.Avoid.oTheoretical
Moderate (7)
Atorvastatin - decreases exposure
Etravirine slightly decreases the exposure to statins (atorvastatin). Monitor and adjust dose.
Fluvastatin - increases exposure
Etravirine is predicted to increase the exposure to statins (fluvastatin). Adjust dose.
Osimertinib - decreases exposure
Etravirine is predicted to decrease the exposure to simertinib. Use with caution or avoid.
Phosphodiesterase Type- - decreases exposure
Etravirine moderately decreases the exposure to phosphodiesterase type-5 inhibitors. Adjust dose.
Simvastatin - decreases exposure
Etravirine is predicted to decrease the exposure to statins (simvastatin). Adjust dose.
Statins - decreases exposure
Etravirine slightly decreases the exposure to statins (atorvastatin). Monitor and adjust dose.
Statins - increases exposure
Etravirine is predicted to increase the exposure to statins (fluvastatin). Adjust dose.
Unknown (15)
Antimalarials - decreases exposure
Etravirine decreases the exposure to antimalarials (artemether).
Artemether - decreases exposure
Etravirine decreases the exposure to antimalarials (artemether).
Avapritinib - decreases exposure
Etravirineispredictedtodecreasetheexposuretoavapritinib. Avoid.rTheoretical
Bedaquiline - decreases exposure
Etravirineispredictedtodecreasetheexposuretobedaquiline. Avoid.rTheoretical
Bosutinib - decreases exposure
Etravirineispredictedtodecreasetheexposuretobosutinib. Avoid.rTheoretical
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Etravirine is an antiviral medication used to treat HIV infection.
What it treats
- HIV infection (human immunodeficiency virus)
- AIDS (acquired immune deficiency syndrome)
How it works
It helps to control the amount of virus in the body, allowing the immune system to work better.
Who it's for
This medicine is for people living with HIV.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Etravirine
BNF-referencedEtravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is indicated for adult and paediatric patients aged 2 years and older who are experienced in antiretroviral treatment. Etravirine is administered in combination with other antiretroviral drugs, including boosted protease inhibitors, to enhance therapeutic efficacy and reduce the viral load in patients with HIV-1.
Indications
- HIV infection in antiretroviral treatment-experienced adults
- HIV infection in antiretroviral treatment-experienced paediatric patients from 2 years of age
Dosage
Children: For paediatric patients aged 2 years and older, refer to the BNF for Children for specific dosing guidelines.
Adults: The recommended initial dose is 200 mg once daily for the first 14 days, followed by a maintenance dose of 200 mg twice daily, to be taken after food.
Mechanism of action
Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of HIV-1. It binds directly to reverse transcriptase, blocking both DNA-dependent and RNA-dependent polymerase activity, while sparing human DNA polymerase alpha, beta, and gamma from inhibition.
Pharmacodynamics
Clinical studies have demonstrated that Etravirine does not prolong QT intervals on electrocardiograms after 8 days of dosing, indicating a favorable cardiac safety profile.
Pharmacokinetics
Etravirine is well absorbed when taken orally, with food enhancing its bioavailability. It is extensively metabolized in the liver via cytochrome P450 enzymes, particularly CYP2C19, CYP2C9, and CYP3A4. The drug has a half-life of approximately 20 to 30 hours, allowing for twice-daily dosing. Etravirine is primarily excreted through feces, with only a small percentage eliminated unchanged in urine.
Contra-indications
- Acute porphyrias
Adverse effects
- Diarrhoea
- Drowsiness
- Dry mouth
- Dyslipidaemia
- Dyspnoea
- Gastrointestinal discomfort
- Headache
- Hyperglycaemia
- Hypersensitivity reactions
- Hypertension
- Memory loss
- Myocardial infarction
- Nausea
- Peripheral neuropathy
- Renal failure
- Rash (usually in the second week)
- Sleep disorders
- Sweat changes
- Thrombocytopenia
- Vision blurred
- Vomiting
- Angina pectoris
- Angioedema
- Atrial fibrillation
- Bronchospasm
- Concentration impaired
- Confusion
- Gynaecomastia
- Haematemesis
- Hepatic disorders
- Immune reconstitution inflammatory syndrome
- Pancreatitis
- Seizure
- Syncope
- Tremor
- Vertigo
- Osteonecrosis
Interactions
- Etravirine + benzodiazepines: Severe (increases exposure)
- Etravirine + diazepam: Severe (increases exposure)
- Etravirine + mobocertinib: Severe (decreases exposure)
- St John's Wort + etravirine: Severe (decreases exposure)
- Etravirine + zanubrutinib: Severe (decreases exposure)
- Etravirine + osimertinib: Moderate (decreases exposure)
- Etravirine + phosphodiesterase type-5 inhibitors: Moderate (decreases exposure)
- Etravirine + statins: Moderate (decreases or increases exposure, depending on the statin)
Precautions
- Caution in elderly patients
- Monitor liver function in patients with hepatic impairment
- Caution in patients with CD4 cell counts greater than 250 cells/mm3
- Caution in patients with severe renal failure
Pregnancy
Reports of neural tube defects when used
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Etravirine
PubChem CID 193962Molecular formula: C20H15BrN6O
Mechanism of action
Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1). It directly binds reverse transcriptase and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma.
Pharmacodynamics
Clinical trials have shown no prolongation of QT intervals on electrocardiograms after 8 days of dosing.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.